CST, 29608S, Human IGF-I Recombinant Protein

Growth Factors and Cytokines for studying IGF1 in the research area. Storage Human IGF-I Recombinant Protein is supplied as lyophilized material that is very stable at -20°C. It is recommended to reconstitute with sterile water at a concentration of 0.1 mg/mL which can be further diluted in aqueous solutions as needed. Addition of a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Once in solution, store at 4°C and use within 1 month, or store at -20ºC to -80ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles if storing reconstituted material at -20ºC to -80ºC. Source / Purification Recombinant human IGF-I was expressed in and is supplied in a lyophilized form. Background Most circulating endocrine acting IGF-I is produced by hepatocytes, and paracrine or autocrine acting IGF-I is produced by defined cell types within specific tissues (1,2). Many neoplastic cells produce IGF-I, which regulates a number of cellular processes, including energy metabolism, proliferation, and cell survival (3,4). IGF-I activity is regulated by one or more of the six extracellular IGF-binding proteins (IGFBPs). IGFBPs bind to IGF-I and most inhibit IGF-I binding to IGF-I receptor (IGF-IR) (1,2). Some IGFBPs may increase cell responses to IGF-I. Binding of IGF-I to IGF-IR activates the Akt, JNK, and Erk pathways (2). IGF-I and IGF-IR are frequently expressed by cancer cells and may contribute to the proliferation and viability of several cancer types (1,2).